Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Receptors [694]) are activated endogenous ligands prostaglandins PGD2, PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Differences similarities between human rodent prostanoid receptor orthologues, their specific roles in pathophysiologic conditions reviewed [448]. Measurement of potency PGI2 A2 is h...

Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Receptors [701]) are activated endogenous ligands prostaglandins PGD2, PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Differences similarities between human rodent prostanoid receptor orthologues, their specific roles in pathophysiologic conditions reviewed [452]. Measurement of potency PGI2 A2 is h...

Pulmonary Arterial Hypertension (PAH) is a devastating disease that, until recently, had no effective medical therapy. In 1996, a prostacyclin, epoprostenol, was approved; since then, several therapies, including prostacyclin analogues and agents that modulate other vasoactive pathways – endothelin receptor antagonists and phosphodiesterase inhibitors – have received approval. In this issue of ...

In this article, I reflect on a 40-year career in drug discovery at Bristol Myers Squibb that encompassed the cardiovascular, central nervous system and antiviral therapeutic areas. share scientific observations made design optimization of cAMP phosphodiesterase inhibitors, prostacyclin partial agonists, maxi-K ion channel openers, influenza respiratory syncytial virus hepatitis C NS3/4A protea...